BTIG raised the firm’s price target on Glaukos (GKOS) to $141 from $131 and keeps a Buy rating on the shares. The company’s Glaucoma and iDose revenue exceeded the firm’s Q1 estimates while Epioxa is off to a strong start with even faster market development and payer coverage, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target raised to $140 from $135 at Citi
- Glaukos Reaffirmed as Buy on Strong Q1 Beat, Raised 2026 Revenue Outlook, and Billion-Dollar Peak Potential for iDose and Epioxa
- Glaukos reports Q1 EPS (18c), consensus (28c)
- Glaukos sees FY26 revenue $620M-$635M, consensus $614.4M
- Glaukos Boosts Outlook After Strong First-Quarter 2026 Results